A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Recruiting

Phase 2

Venetoclax & AzacitidineA Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Sponsor:

OncoVerity, Inc.

Code:

NCT06384261

Conditions

Leukemia, Myeloid, Acute

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cusatuzumab

Venetoclax

Azacitidine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-18. This information was provided to ClinicalTrials.gov by OncoVerity, Inc. on 2025-09-10.